FDA approves Teva cancer treatment biosimilar

Tbo-filgrastim is a biosimilar of Amgen's biologic drug Neupogen.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has obtained US Food and Drug Administration (FDA) approval tbo-filgrastim, a biological drug for the treatment of severe neutropenia (a reduction in white blood cells. in patients receiving chemotherapy for certain types of cancer. Tbo-filgrastim is a biosimilar (or copy) of Amgen Inc.'s (Nasdaq: AMGN) biologic drug Neupogen.

Tbo-filgrastim is a short-acting recombinant form of granulocyte colony-stimulating factor (G-CSF) to stimulate the bone marrow to produce white bloods cells to reduce the duration of severe neutropenia, which can make patients more susceptible to potentially life-threatening bacterial infections.

Teva already markets filgrastim in Europe under the trade name Tevagrastim, and plans to begin marketing in the US by November 2013, under the terms of a settlement reached with Amgen.

Teva chief scientific officer and global R&D president Dr. Michael Hayden said, "The approval of tbo-filgrastim demonstrates Teva's strong commitment to providing patients with new treatment options. It expands upon Teva's existing oncology portfolio with the addition of the first biologic and supportive care agent for oncology patients."

Published by Globes [online], Israel business news - www.globes-online.com - on August 30, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס